XRN Stock Forecast & Price Target

Chiron Real Estate is attractive because it is executing a deliberate pivot from legacy medical office assets into higher-growth SHOP and active adult housing, supported by trophy-quality acquisitions in supply-constrained markets and a repeatable development-to-acquisition pipeline. The balance sheet transition looks manageable, with $266mm of dispositions funding $249mm of SHOP acquisitions, net debt to adjusted EBITDAre improving to 6.0x, $642mm of total debt, 78% fixed-rate exposure, a 4.6% weighted average interest rate, and no debt maturities until 2028. Although FAD per share is expected to trough in 2026-2027 as lease-up creates near-term dilution, management’s hiring of specialized senior housing talent, same-store cash NOI growth of 3.2%, and implied 7%+ stabilized yields suggest a credible path to stronger earnings and a re-rating as execution risk declines.

Chiron Real Estate is facing a negative setup because its 2026 and 2027 FFO estimates of $3.10 and $2.57 imply a -17.1% y/y decline next year and another drop as lease-up costs, interest expense, preferred dividends, and G&A run ahead of NOI from assets still stabilizing. The company also cut its dividend 36% to $0.16 per month, withdrew 2026 guidance, and trades at 14.8x 2027E AFFO despite being the only peer expected to post a 2027E AFFO decline, underscoring near-term earnings pressure. On top of that, its concentration in a limited set of states and reliance on healthcare tenants exposes it to reimbursement, regulatory, economic, and tenant credit risk, while even a modest slowdown in rent growth or a large tenant default could pressure cash flow and sentiment.